EnClear Therapies utilizes its proprietary EnTrega CSF Platform to deliver precision dosing of therapeutics directly to the central nervous system, minimizing severe side effects and peripheral toxicity. The company focuses on treating neuro-oncology and expanding into neurodegenerative, lysosomal storage, and autoimmune diseases, addressing the critical need for effective CNS disease management.
Funding
$12.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Treating central nervous system (CNS) diseases like neuro-oncology and neurodegenerative disorders is challenging due to the blood-brain barrier, which limits drug delivery and can result in severe side effects and peripheral toxicity. Effective CNS disease management requires precise therapeutic dosing to maximize efficacy while minimizing harm.
Solution
EnClear Therapies is developing the EnTrega CSF Platform, a closed-loop system for precision dosing of therapeutics directly to the central nervous system. This platform aims to achieve efficacious drug levels in the CNS while reducing the risk of severe side effects and peripheral toxicity. By delivering therapeutics directly to the cerebrospinal fluid (CSF), EnClear seeks to overcome the limitations of systemic drug administration and improve outcomes for patients with CNS diseases. The platform integrates machine learning (ML) and artificial intelligence (AI) to optimize dosing strategies.
Target Audience
The primary target audience includes patients suffering from central nervous system (CNS) disorders such as neurodegenerative diseases and CNS malignancies.
Features
- Closed-loop CSF control for precise therapeutic delivery
- Integrated machine learning and artificial intelligence for optimized dosing
- Targeted delivery to the CNS, bypassing the blood-brain barrier
- Reduced risk of severe side effects and peripheral toxicity